|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yeh JM, Kuntz KM, Ezzati M, Hur C, Kong CY
and Goldie SJ: Development of an empirically calibrated model of
gastric cancer in two high-risk countries. Cancer Epidemiol
Biomarkers Prev. 17:1179–1187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J,
Lee J, Provost P, Rådmark O, Kim S and Kim VN: The nuclear RNase
III Drosha initiates microRNA processing. Nature. 425:415–419.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao H, Guo M, Zhao G, Ma Q, Ma B, Qiu X
and Fan Q: miR-183 inhibits the metastasis of osteosarcoma via
downregulation of the expression of Ezrin in F5M2 cells. Int J Mol
Med. 30:1013–1020. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schaefer A, Jung M, Mollenkopf HJ, Wagner
I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G and Jung
K: Diagnostic and prognostic implications of microRNA profiling in
prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.
|
|
9
|
Wang J, Zhou Y, Fei X, Chen X and Chen Y:
Biostatistics mining associated method identifies AKR1B10 enhancing
hepatocellular carcinoma cell growth and degenerated by miR-383-5p.
Sci Rep. 8:110942018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Kong X, Shi Q and Zhao B:
MicroRNA-383-5p acts as a potential prognostic biomarker and an
inhibitor of tumor cell proliferation, migration, and invasion in
breast cancer. Cancer Biomark. 27:423–432. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu Y, Ma Y, Liu J, Cai Y, Zhang M and Fang
X: LINC01128 expedites cervical cancer progression by regulating
miR-383-5p/SFN axis. BMC Cancer. 19:11572019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shao B, Fu X, Li X, Li Y and Gan N:
RP11-284F21.9 promotes oral squamous cell carcinoma development via
the miR-383-5p/MAL2 axis. J Oral Pathol Med. 49:21–29. 2020.
View Article : Google Scholar
|
|
13
|
Wei C and Gao JJ: Downregulated miR-383-5p
contributes to the proliferation and migration of gastric cancer
cells and is associated with poor prognosis. Peer J. 7:e78822019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu G, Li N, Zhang Y, Zhang J, Xu R and Wu
Y: MicroRNA-383-5p inhibits the progression of gastric carcinoma
via targeting HDAC9 expression. Braz J Med Biol Res. 52:e83412019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Soo Hoo L, Zhang JY and Chan EK: Cloning
and characterization of a novel 90 kDa 'companion' auto-antigen of
p62 overexpressed in cancer. Oncogene. 21:5006–5015. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP,
Cui QZ and Wang EH: CIP2A is overexpressed in non-small cell lung
cancer and correlates with poor prognosis. Ann Surg Oncol.
18:857–865. 2011. View Article : Google Scholar
|
|
17
|
Huang LP, Adelson ME, Mordechai E and
Trama JP: CIP2A expression is elevated in cervical cancer. Cancer
Biomark. 8:309–317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vaarala MH, Väisänen MR and Ristimäki A:
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer
Res. 29:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia
J and Xu D: CIP2A is overexpressed in gastric cancer and its
depletion leads to impaired clonogenicity, senescence, or
differentiation of tumor cells. Clin Cancer Res. 14:3722–3728.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao S, Gao X, Zang S, Li Y, Feng X and
Yuan X: MicroRNA-383-5p acts as a prognostic marker and inhibitor
of cell proliferation in lungadenocarcinoma by cancerous inhibitor
of protein phosphatase 2A. Oncol Lett. 14:3573–3579. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M,
De W, Wang C and Ji G: LincRNAFEZF1-AS1 represses p21 expression to
promote gastric cancer proliferation through LSD1-mediated H3K4me2
demethylation. Mol Cancer. 16:392017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang S, Wang X, Gao Y, Peng Y, Dong N, Xie
Q, Zhang X, Wu Y, Li M and Li JL: RN181 is a tumour suppressor in
gastric cancer by regulation of the ERK/MAPK-cyclin D1/CDK4
pathway. J Pathol. 248:204–216. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Korsmeyer SJ, Shutter JR, Veis DJ, Merry
DE and Oltvai ZN: Bcl-2/Bax: A rheostat that regulates an
anti-oxidant pathway and cell death. Semin Cancer Biol. 4:327–332.
1993.PubMed/NCBI
|
|
25
|
Chen L, Guan H, Gu C, Cao Y, Shao J and
Wang F: miR-383 inhibits hepatocellular carcinoma cell
proliferation via targeting APRIL. Tumour Biol. 37:2497–2507. 2016.
View Article : Google Scholar
|
|
26
|
Han S, Cao C, Tang T, Lu C, Xu J, Wang S,
Xue L, Zhang X and Li M: ROBO3 promotes growth and metastasis of
pancreatic carcinoma. Cancer Lett. 366:61–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He Z, Cen D, Luo X, Li D, Li P, Liang L
and Meng Z: Downregulation of miR-383 promotes glioma cell invasion
by targeting insulin-like growth factor 1 receptor. Med Oncol.
30:5572013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen S, Wu J, Jiao K, Wu Q, Ma J, Chen D,
Kang J and Zhao G, Shi Y, Fan D and Zhao G: MicroRNA-495-3p
inhibits multidrug resistance by modulating autophagy through
GRP78/mTOR axis in gastric cancer. Cell Death Dis. 9:10702018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang F, Li K, Pan M, Li W, Wu J, Li M,
Zhao L and Wang H: miR-589 promotes gastric cancer aggressiveness
by a LIFR-PI3K/AKT-c-Jun regulatory feedback loop. J Exp Clin
Cancer Res. 37:1522018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang J, Xie C, Liu Y, Shi Q and Chen Y:
Up-regulation of miR-83-5p suppresses proliferation and enhances
chemosensitivity in ovarian cancer cells by targeting TRIM27.
Biomed Pharmacother. 109:595–601. 2019. View Article : Google Scholar
|
|
31
|
Chao TT, Wang CY, Lai CC, Chen YL, Tsai
YT, Chen PT, Lin HI, Huang YC, Shiau CW, Yu CJ and Chen KF: TD-19,
an erlotinib derivative, induces epidermal growth factor receptor
wild-type nonsmall-cell lung cancer apoptosis through
CIP2A-mediated pathway. J Pharmacol Exp Ther. 351:352–358. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lei N, Peng B and Zhang JY: CIP2A
regulates cell proliferation via the AKT signaling pathway in human
lung cancer. Oncol Rep. 32:1689–1694. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhai H, Fesler A, Schee K, Fodstad O,
Flatmark K and Ju J: Clinical significance of long intergenic
noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer.
12:261–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pozner A, Terooatea TW and Buck-Koehntop
BA: Cell-specific kaiso (ZBTB33) regulation of cell cycle through
cyclin D1 and cyclin E1. J Biol Chem. 291:24538–24550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oda E, Ohki R, Murasawa H, Nemoto J,
Shibue T, Yamashita T, Tokino T, Taniguchi T and Tanaka N: Noxa, a
BH3-only member of the Bcl-2 family and candidate mediator of
p53-induced apoptosis. Science. 288:1053–1058. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
LeBlanc H, Lawrence D, Varfolomeev E,
Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and
Ashkenazi A: Tumor-cell resistance to death receptor-induced
apoptosis through mutational inactivation of the proapoptotic Bcl-2
homolog Bax. Nat Med. 8:274–281. 2002. View Article : Google Scholar : PubMed/NCBI
|
